Amonafide: A potential role in treating acute myeloid leukemia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 995-1003

  Allen, Steven L ^a   Lundberg, Ante S ^b  

^a North Shore Long Island Center for Advanced Medicine   (United States)

^b Antisoma   (United States)

Author keywords

acute myeloid leukemia; amonafide; elderly; leukemia; poor risk populations; topoisomerase II inhibitor

Indexed keywords

AMONAFIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG METABOLITE; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; N ACETYLAMONAFIDE; NORAMONAFIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APPETITE; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CYTOGENETICS; CYTOTOXICITY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG TREATMENT FAILURE; ERYTHEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; KARYOTYPE; LEUKEMIA REMISSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MYELOBLAST; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN PAIN; SKIN TOXICITY; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NAPHTHALIMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79958842299     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.585756     Document Type: Article

References (35)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74
2. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9
3. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998;20:3607-15 (Pubitemid 28225726)
4. Larson RA. Is secondary AML an independent poor prognostic factor in AML? Best Pract Res Clin Haematol 2007;20(1):29-37
5. Kayser S, Dohner K, Krauter J, et al., The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117(7):2137-45
6. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869-76 (Pubitemid 35396851)
7. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5
8. Pirker R, Wallner J, Geissler K, et al. MDR 1 gene expression and treatment outcome in acute myeloid leukemia. Cancer Inst 1991;83:708-12
9. Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997;34(4 Suppl 5):25-33 (Pubitemid 28032417)
10. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34 (Pubitemid 43336035)
11. Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 2009;12:246-52
12. Baer MR. Clinical significance of multidrug resistance in AML: current insights. Clin Adv Hematol Oncol 2005;3:910-12 (Pubitemid 43168747)
13. Baer MR, George SL, Dodge RK, et al. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32 (Pubitemid 34864276)
14. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high risk myelodysplastic syndrome: a Phase III trial (E2995). J Clin Oncol 2004;22:1078-86 (Pubitemid 41095041)
15. Cripe LD, Li X, Litzow M, et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for Pts >60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood 2006;108:129a
16. Matsouka P, Pagoni M, Zikos P, et al. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. Ann Hematol 2006; 85(4):250-617
17. Otake Y, Chau M, Ajami AM, et al. Amonafide interferes with topoisomerase II binding to DNA and induces chromatin disorganization. AACR Meeting Abstracts 2008; Abs 647. Proc AACR 2008;49:152
18. Brana MF, Castellano JM, Roldan CM, et al. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid. Cancer Chemother Pharmacol 1980;4:61-6 (Pubitemid 10135703)
19. Otake Y, Chau M, Capizzi RL, et al. Amonafide (AS1413) intercalates into DNA and is a unique inhibitor of DNA topoisomerase II. AACR Meeting Abstracts 2009; Abs 5858. Proc AACR
20. Danks MK, Schmidt CA, Cirtain MC, et al. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988;27:8861-9 (Pubitemid 19008203)
21. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993;53:5946-53 (Pubitemid 24006165)
22. Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 2008;32:465-73 (Pubitemid 351295924)
23. Burcu M, O'Loughlin KL, Ford LA, Baer MR. Amonafide l-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 2008;22:2110-15
24. Antisoma Research Ltd. Amonafide Investigator's Brochure. Version 8. 13 February 2009
25. Kreis W, Chan K, Budman DR, et al. Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients. Cancer Invest 1996;14:320-7 (Pubitemid 26249169)
26. Felder TB, McLean MA, Vestal ML, et al. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab Dispos 1987;15:773-8 (Pubitemid 18019768)
27. O'Brien S, Benvenuto JA, Estey E, et al. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 1991;51:935-8
28. Allen SL, Kolitz JE, Lundberg AS, et al. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 2010;34:487-91
29. Erba HP. The combination of xanafide and cytarabine has unique activity in acute myeloid leukemia. Touch Briefings. Eur Oncol Dis 2007;2:30-1
30. Allen SL, Erba HP, Rizzieri DA, et al. Secondary acute myeloid leukemia (s AML) treated with amonafide (AS1413) + cytarabine: durable responses in poor-risk AML. ASH Annual Meeting Abstracts 2008; Abs 2968. Blood Nov 2008;112:2968
31. Lundberg A, Chau M, Erba HP, et al. Amonafide (AS1413) is unaffected by multidrug resistance and is associated with a high response rate in patients with secondary AML. EHA Annual Meeting Abstracts 2009: Abs 1058
32. Erba HP, O'Donnell M, Allen SL, et al. Amonafide (AS1413) in combination with cytarabine is equally effective in older and younger patients with secondary acute myeloid leukemia (sAML); final data from a Phase II study. ASH Annual Meeting Abstracts 2009: Abs 1047. Blood 2009;114:1047
33. Downie BJ, Erba HP, Stone RM, et al. Monosomal karyotype is predictive of poor response to therapy and worse overall survival in secondary acute myeloid leukemia (sAML); analysis of a multi-center phase II study of amonafide and cytarabine induction therapy. ASH Annual Meeting Abstracts: Abs 2076. Blood 2009;114:2076
34. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791-7
35. Lowenberg B, Ossenkopppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361(13):1235-48